Bloomberg News

OncoMed Jumps After Signing $177 Million Deal With Celgene (2)

December 03, 2013

OncoMed Pharmaceuticals Inc. (OMED:US), a drug developer that first sold shares to the public in July, almost doubled in trading after signing a $177.25 million agreement with Celgene Corp. (CELG:US) on as many as six potential cancer medicines.

OncoMed rose 98 percent to $27.70 at the close in New York in the biggest one-day rise since the company’s initial public offering. The shares of the Redwood City, California-based company have gained 63 percent since the IPO.

The deal includes a $22.25 million equity investment and additional payments tied to development and sales goals which may total more than $3 billion, the companies said today in a statement. OncoMed, whose drugs target cancer stem cells, will oversee early clinical studies, and Summit, New Jersey-based Celgene will then have the option to license worldwide rights to the compounds.

Celgene, the world’s fourth-largest biotechnology company, gets an exclusive option on OncoMed’s demcizumab, which is in early stage studies in diseases including pancreatic cancer. Celgene shares, which have doubled this year, declined 2 percent to $159.93.

OncoMed was advised by Latham & Watkins LLP and Leerink Swann LLC. The company also has partnerships with Bayer AG (BAYN) and GlaxoSmithKline Plc.

To contact the reporter on this story: Meg Tirrell in New York at

To contact the editor responsible for this story: Reg Gale at

The Aging of Abercrombie & Fitch

Companies Mentioned

  • OMED
    (OncoMed Pharmaceuticals Inc)
    • $22.41 USD
    • -0.31
    • -1.38%
  • CELG
    (Celgene Corp)
    • $123.89 USD
    • 0.18
    • 0.15%
Market data is delayed at least 15 minutes.
blog comments powered by Disqus